With Peter Hunt AM, Dr Michael Winlo and Prof Alistair Vickery
Date: Wed 10 March 2021 @ 7:30pm
Location: Online
Join this FREE, 60-minute online webinar to gain access to insights and learn about groundbreaking treatments to chronic mental health conditions.
Global interest and investment in psychedelic medicine companies is accelerating. However, these treatments are not like typical medicines. The patient experience and clinical care model is intense and also deeply, and necessarily, intertwined. So, the question arises, how can we develop care delivery models for these treatments that are safe, effective but also commercially viable? We will explore these themes with clinical service partner Emyria. We will explore how we are approaching these challenges and learn from Emryia’s experience creating an evidence-generating care model for medicinal cannabis.
This FREE webinar will explore:
WEBINAR SESSION
Date: Wednesday 10 March 2021
Time: 7:25pm for 7:30pm start – 8:45pm (incl Q&A) (AEDT)
The presentation WILL BEGIN AT 7:30pm.
Location: Online. A link will be emailed to you with the viewing details once you have registered.
Following the presentation there will be a Q & A panel with Peter Hunt AM, Chairman and Co-founder of Mind Medicine Australia, Dr Michael Winlo, Managing Director of Emryia and Professor Alistair Vickery, Executive Medical Director of Emryia. This will be an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.
Support these events:
Whilst our webinars are free of charge, we strongly encourage you to make a donation and support our important mission of making these therapies available through our medical system. This can be done at the time of reserving your ticket. Please share these events with your networks.
More about medicinal psychedelic treatments:
Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.
The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.
B.Com, LL.B
As an investment banker Peter Hunt AM advised local and multi-national companies and governments in Australia for nearly 35 years. He co-founded one of Australia’s leading investment banking advisory firms, Caliburn Partnership and was Executive Chairman of Greenhill Australia. Peter was a member of the Advisory Panel of ASIC and chaired the Vincent Fairfax Family Office.
Peter is an active philanthropist involved in funding, developing and scaling social sector organisations which seek to create a better and fairer world. He is Chairman of Mind Medicine Australia which he established with his wife, Tania de Jong, in 2018. He regularly presents to Governments, regulators, clinicians, philanthropists and the general public on psychedelic-assisted therapies and the legal and ethical frameworks needed to ensure these treatments can be made accessible and affordable. He was the lead author of Mind Medicine Australia’s successful rescheduling applications for MDMA and psilocybin, which made Australia the first country in the world to reschedule these medicines.
He founded Women’s Community Shelters in 2011. Peter is a Director of The Umbrella Foundation. Peter also acts as a pro bono adviser to Creativity Australia. He was formerly Chairman of So They Can, Grameen Australia and Grameen Australia Philippines.
Peter was made a member of the General Division of the Order of Australia in the Queen’s Birthday Honours List in 2010 for services to the philanthropic sector.
Dr Michael Winlo, chief executive of Emerald Clinics since August 2019, was chief executive of Linear
Clinical Research for 3 years and remained on the board from July 2019 when he stepped down from the
CEO role to lead a startup company in digital health innovation. Linear Clinical Research is the clinical
trials arm of the Harry Perkins Institute of Medical Research. Dr Winlo holds a Bachelor of Medicine and
Surgery from the University of Western Australia, and an MBA from the Stanford Graduate School of
Business. He was a co-founder of medical device startup Cerulean Medical in 2007, and spent five years
in the US growing the health practice of data analysis firm Palantir Technologies
Alistair is the medical director of Emerald Clinics and has a wealth of expertise in clinical practice, health service management, clinical and educational research and board director skills. He is adjunct Clinical Professor of Primary Health Care at the University of Western Australia and Notre Dame University and an active specialist general practitioner. He is the clinical lead of the research group CHASM (The Collaborative for Health Care Analysis and Statistical Modelling) – providing high-level analysis and statistical modelling to inform WA Health clinical service planning and service evaluation. Alistair is Board Chair of Black Swan Health, one of the largest NFP primary health care, disability, and mental health services in Australia. Alistair is a Fellow of the Australasian College of Health Service Management and an AICD graduate.
Disclaimer: Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example Facebook, Instagram or Zoom private and public chat forms during a webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.
